CNTB Connect Biopharma Holdings Ltd

Nasdaq connectbiopharm.com


$ 1.70 $ -0.10 (-5.46 %)    

Friday, 17-Oct-2025 15:59:52 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.73
$ 1.82
$ 1.50 x 1
$ 1.99 x 1,565
$ 1.73 - $ 1.85
$ 1.23 - $ 2.20
36,759
na
117.1M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 connect-biopharma-presents-data-supporting-rademikibart-next-gen-anti-interleukin-4-receptor-alpha-antibody-at-ers-congress-2025

– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest im...

 hc-wainwright--co-reiterates-buy-on-connect-biopharma-hldgs-maintains-7-price-target

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 ...

 connect-biopharma-hldgs-q2-eps-023-misses-022-estimate-sales-48000k-down-from-24116m-yoy

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimat...

 connect-biopharma-to-terminate-adr-program-and-list-ordinary-shares-directly-on-nasdaq

Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage bioph...

 connect-biopharma-holdings-announces-companys-collaborator-and-exclusive-licensee-in-china-simcere-pharmaceutical-has-submitted-its-new-drug-application-for-rademikibart-to-the-national-medical-products-administration-of-china-for-the-treatment-of-atopic-dermatitis

Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a ...

 connect-biopharma-presents-clinical-data-supporting-rademikibart-anti-interleukin-4-receptor-alpha-antibody-at-eaaci-2025-annual-congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –– Ra...

 hc-wainwright--co-assumes-connect-biopharma-hldgs-at-buy-announces-price-target-of-7

HC Wainwright & Co. analyst Brandon Folkes assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces...

 connect-biopharma-files-for-mixed-shelf-offering-of-up-to-300m

-SEC Filing

 connect-biopharma-presents-clinical-and-preclinical-data-supporting-rademikibart-at-ats-2025-international-conference

– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacer...

 connect-biopharma-hldgs-q1-eps-019-down-from-016-yoy

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.19) per share. This is a 18.75 percent decrease over los...

 connect-biopharma-initiates-phase-2-seabreeze-stat-copd-study-following-written-agreement-on-final-study-protocol-from-fda-expects-to-report-topline-data-in-1h-2026

– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 –SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Conn...

 connect-biopharma-initiates-phase-2-seabreeze-stat-asthma-study-evaluating-rademikibart-for-acute-exacerbations-in-asthma

– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 –– On track to initiate similarly-designed Phas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION